Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study
Cancers (Basel). 2025 Mar 28;17(7):1137. doi: 10.3390/cancers17071137.ABSTRACTBACKGROUND/OBJECTIVES:…
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
Ann Oncol. 2025 Apr 8:S0923-7534(25)00135-8. doi: 10.1016/j.annonc.2025.04.001.…
Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis
Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02557-7.…
Lead exposure, peripheral neurotransmitter levels and cognitive control: A neurobehavioral study in children from Montevideo, Uruguay
Neurotoxicology. 2025 Apr 4:S0161-813X(25)00035-X. doi: 10.1016/j.neuro.2025.03.009.…
Prizloncabtagene autoleucel: a new CAR T cell for B-NHL
Blood. 2025 Apr 3;145(14):1444-1445. doi: 10.1182/blood.2024028030.NO…
Celebrating 5 years of Women in Lymphoma: a road to equality, diversity, and inclusion in the field
Lancet Haematol. 2025 Apr;12(4):e246-e247. doi: 10.1016/S2352-3026(25)00070-5.NO…
Autologous Stem Cell Transplantation for Relapsed/Refractory Large B Cell Lymphoma: Multicenter GETH-TC/GELTAMO Study
Blood Adv. 2025 Mar 31:bloodadvances.2024015415. doi: 10.1182/bloodadvances.2024015415.…
Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma
Bone Marrow Transplant. 2025 Mar 27. doi: 10.1038/s41409-025-02539-9.…
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer
Nat Commun. 2025 Mar 10;16(1):2374. doi: 10.1038/s41467-025-57470-w.ABSTRACTUveal…
Unraveling the power of NAP-CNB’s machine learning-enhanced tumor neoantigen prediction
Elife. 2025 Mar 11;13:RP95010. doi: 10.7554/eLife.95010.ABSTRACTIn…
Harnessing STING Signaling and Natural Killer Cells overcomes PARP Inhibitor Resistance in Homologous Recombination Deficient Breast Cancer
Cancer Res. 2025 Mar 11. doi: 10.1158/0008-5472.CAN-24-2531.…
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment
NAR Cancer. 2025 Mar 7;7(1):zcaf007. doi: 10.1093/narcan/zcaf007.…
